Amendment #1 to Collaboration Agreement, effective as of December 31, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be The Match BioTherapies, dated as of November 10, 2017
This Amendment #1 (Amendment #1) is issued pursuant to the Collaboration Agreement (Agreement), effective November 10, 2017, between Magenta Therapeutics, Inc. (Magenta) and National Marrow Donor Program d/b/a Be The Match BioTherapies (BTMB) and incorporates all of the terms and conditions therein. The effective date of this Amendment shall be December 31, 2020.
The Parties agree to extend the term under the Agreement as follows:
Replace Section 2. Term in its entirety to read as follows:
2. Term. The term of this Agreement shall commence on the effective date set forth above and continue and remain in effect until December 31, 2022 or until this Agreement is terminated as provided for in Section 9, Termination.
Except as provided above, all other terms and conditions in the Agreement remain unchanged and in full force and effect. This Amendment #1 is executed by individuals who are authorized to bind their respective parties.
|NATIONAL MARROW DONOR |
PROGRAM d/b/a BE THE MATCH
|MAGENTA THERAPEUTICS, INC.|
|By:||/s/ Mary Frey||By:||/s/ Christina Isacson|
|Authorized signature||Authorized signature|
|Mary Frey||Christina Isacson|
|(Typed/Printed Name)||(Typed/Printed Name)|
|Title:||Contracts & Procurement Director||Title:||Chief Business Officer|